Fei Xu

Fei Xu

Auto-generated profile, based on publicly available information

Fei Xu

Department of Basic Medicine Wuxi School of Medicine, Jiangnan University Wuxi Jiangsu People's Republic of China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2026 in Cancer Medicine
Verified
Journal Article
Open access
YZYutian Zhao
Yutian Zhao
JZJiahao Zhu
Jiahao Zhu
BXBenjie Xu
Benjie Xu
PSPeipei Shen
Peipei Shen
FXFei Xu
Fei Xu
LZleyuan zhou
leyuan zhou
Objective: To investigate the impact of diagnostic and treatment delays on the prognosis of patients with locally advanced rectal cancer (LARC). Methods: Retrospective analyses were performed in Chinese and American cohorts. The intervals from symptom onset to diagnosis and from diagnosis to initial treatment were defined as diagnostic and treatment delays. A univariate and multivariable Cox regression model was conducted for overall survival (OS), cancer‐specific survival (CSS), and disease‐free survival (DFS). Results: A total of 450 Chinese and 5810 American patients were included in this study. Multivariable analysis revealed that a prolonged diagnostic delay (> 5 months) was significantly associated with decreased OS (hazard ratio [HR]: 1.50, p = 0.041) and DFS (HR: 1.36, p = 0.047). Additionally, an extended treatment delay (> 2 months) was closely associated with reduced OS (> 1 and ≤ 2 months vs. ≤ 1 month, HR: 1.06, p = 0.386; > 2 months vs. ≤ 1 month, HR: 1.52, p < 0.001) and CSS (> 1 and ≤ 2 months vs. ≤ 1 month, HR: 1.03, p = 0.693; > 2 months vs. ≤ 1 month, HR: 1.58, p = 0.001) in patients with LARC. Conclusion: Diagnostic intervals exceeding 5 months and treatment delays of more than 2 months are significantly associated with unfavorable survival outcomes in LARC patients. These findings underscore the importance of timely diagnostic pathways and treatment initiation and may serve as clinically meaningful benchmarks for healthcare systems to optimize referral processes, resource allocation, and quality‐of‐care assessment in rectal cancer management.